Childhood AML exhibits distinct biological characteristics compared to adult AML, including higher frequencies of core-binding factor translocations (e.g., t(8;21) and inv(16)) and lower incidence of adverse genetic markers like FLT3-ITD, which necessitate age-specific treatment strategies [4,5,6]. Here, FLT3 is linked to acute myeloid leukemia.